Literature DB >> 7093104

The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.

E Agabiti-Rosei, C L Alicandri, M Beschi, M Castellano, R Fariello, E Montini, M L Muiesan, G Romanelli, G Muiesan.   

Abstract

1 Labetalol 100 mg was given intravenously to 27 patients with essential hypertension (12 males, 15 females; WHO I-II; age range 30-66 yr; on average, a significant reduction of blood pressure was observed within 5 min (P less than 0.001). Average heart rate was also reduced significantly (P less than 0.01). 2 In 18 patients haemodynamic measurements were performed (dye-dilution or thermodilution technique): blood pressure reduction was related to peripheral vasodilatation, as cardiac index remained unmodified. 3 The absolute and percentage decrease of blood pressure, heart rate and total peripheral resistance after labetalol 100 mg intravenously, was significantly greater in the patients with higher baseline plasma noradrenaline concentration values. 4 In 12 out of 27 patients labetalol was given orally for 2 months (dose range 300-1200 mg); the pattern of blood pressure and heart rate changes after oral therapy were comparable to those observed after acute administration of the drug. 5 The degree of blood pressure and heart rate reductions after oral labetalol was also significantly related to pretreatment basal noradrenaline concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093104      PMCID: PMC1401846          DOI: 10.1111/j.1365-2125.1982.tb01894.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Catecholamines-cyclic amp-angiotensin receptors. Plasma catecholamine concentrations in patients with hypertension.

Authors:  K Engelman; B Portnoy; A Sjoerdsma
Journal:  Circ Res       Date:  1970-07       Impact factor: 17.367

2.  Sympatho-adrenal activity inphysical exercise.

Authors:  U S Von Euler
Journal:  Med Sci Sports       Date:  1974

3.  Raised plasma-catecholamines in some patients with primary hypertension.

Authors:  V DeQuattro; S Chan
Journal:  Lancet       Date:  1972-04-15       Impact factor: 79.321

4.  Plasma norepinephrine levels in essential hyoertension.

Authors:  W J Louis; A E Doyle; S Anavekar
Journal:  N Engl J Med       Date:  1973-03-22       Impact factor: 91.245

5.  The relationship between plasma catecholamine concentration and pulse rate during exercise and standing.

Authors:  N J Christensen; O Brandsborg
Journal:  Eur J Clin Invest       Date:  1973-07       Impact factor: 4.686

6.  A sensitive and specific fluorimetric method for the determination of noradrenalin and adrenalin in human plasma.

Authors:  V Renzini; C A Brunori; C Valori
Journal:  Clin Chim Acta       Date:  1970-12       Impact factor: 3.786

7.  Age-adjusted plasma norepinephrine levels are similar in normotensive and hypertensive subjects.

Authors:  C R Lake; M G Ziegler; M D Coleman; I J Kopin
Journal:  N Engl J Med       Date:  1977-01-27       Impact factor: 91.245

8.  Letter: Intravenous labetalol in severe hypertension.

Authors:  E A Rosei; P M Trust; J J Brown; A F Lever; J I Robertson
Journal:  Lancet       Date:  1975-11-29       Impact factor: 79.321

9.  Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

Authors:  J Mehta; J N Cohn
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

10.  Circulating catecholamine levels in human and experimental hypertension.

Authors:  J de Champlain; L Farley; D Cousineau; M R van Ameringen
Journal:  Circ Res       Date:  1976-02       Impact factor: 17.367

View more
  8 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

3.  Evaluation of I.V. labetalol for treatment of posttraumatic hyperdynamic state.

Authors:  D R Morel; A Forster; P M Suter
Journal:  Intensive Care Med       Date:  1984       Impact factor: 17.440

4.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 5.  Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

Authors:  P Lund-Johansen; P Omvik
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

6.  Ketanserin in essential hypertension: effects during rest and exercise.

Authors:  B Persson; T Hedner; G Berglund
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 8.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.